Federal Register / Vol. 86, No. 17 / Thursday, January 28, 2021 / Notices 7401 

is particularly interested in comments 

that: 

(a) Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

(b) Evaluate the accuracy of the 

agencies estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

(c) Enhance the quality, utility, and 

clarity of the information to be 

collected; 

(d) Minimize the burden of the 

collection of information on those who 

are to respond, including, through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submission of 

responses; and 

(e) Assess information collection 

costs. 

To request additional information on 

the proposed project or to obtain a copy 

of the information collection plan and 

instruments, call (404) 639–7570. 

Comments and recommendations for the 

proposed information collection should 

be sent within 30 days of publication of 

this notice to www.reginfo.gov/public/ 

do/PRAMain. Find this particular 

information collection by selecting 

‘‘Currently under 30-day Review—Open 

for Public Comments’’ or by using the 

search function. Direct written 

comments and/or suggestions regarding 

the items contained in this notice to the 

Attention: CDC Desk Officer, Office of 

Management and Budget, 725 17th 

Street NW, Washington, DC 20503 or by 

fax to (202) 395–5806. Provide written 

comments within 30 days of notice 

publication. 

Proposed Project 

Rapid Response Suicide Investigation 

Data Collection (OMB Control No. 

0920–1243, Exp. 09/30/2021)— 

Extension—National Center for Injury 

Prevention and Control (NCIPC), 

Centers for Disease Control and 

Prevention (CDC). 

Background and Brief Description 

CDC is frequently called upon to 

respond to urgent requests from one or 

more external partners (e.g., local, state, 

territory, and tribal health authorities; 

other federal agencies; local and state 

leaders; schools; or other partner 

organizations) to conduct investigations 

of suicide. Supporting rapid 

investigations to inform the 

implementation of effective suicide 

prevention strategies is one of the most 

important ways CDC can serve to 

protect and promote the health of the 

public. 

Rapid Response Suicide Investigation 

Data Collections are specifically 

designed to inform the implementation 

of prevention strategies in a state, 

county, community, or vulnerable 

population where a possible suicide 

cluster or increasing trend has been 

observed. This generic clearance will 

not be used to conduct research studies 

or to collect data designed to draw 

conclusions about the United States or 

areas beyond the defined geographic 

location or vulnerable population that is 

the focus of the investigation. CDC in 

collaboration with external partners 

(e.g., local, state, territory, and tribal 

health authorities; other federal 

agencies; local and state leaders; 

schools; or other partner organizations) 

will identify the respondent universe for 

each Rapid Response Suicide 

Investigation Data Collection. The 

respondent universe will be determined 

based on the information needed to 

understand potential suicide clusters, 

significant increases in suicidal 

behavior and suicide, risk and 

protective factors, and vulnerable 

populations in order to inform the 

implementation of suicide prevention 

strategies. When the goal is 

generalizability, CDC will submit the 

sampling methods to OMB as part of the 

GenIC package. The estimated annual 

burden hours are 1,000. There are no 

costs to respondents other than their 

time. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Rapid Response Suicide Investigation Data Collection 

Participants.

Rapid Response Suicide Investigation Protocol.2,000 1 30/60 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Scientific Integrity, Office of Science, 

Centers for Disease Control and Prevention. 

[FR Doc. 2021–01917 Filed 1–27–21; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[Document Identifier: CMS–10332] 

Agency Information Collection 

Activities: Submission for OMB 

Review; Comment Request 

AGENCY: Centers for Medicare & 

Medicaid Services, Health and Human 

Services (HHS). 

ACTION: Notice. 

SUMMARY: The Centers for Medicare & 

Medicaid Services (CMS) is announcing 

an opportunity for the public to 

comment on CMS’ intention to collect 

information from the public. Under the 

Paperwork Reduction Act of 1995 

(PRA), federal agencies are required to 

publish notice in the Federal Register 

concerning each proposed collection of 

information, including each proposed 

extension or reinstatement of an existing 

collection of information, and to allow 

a second opportunity for public 

comment on the notice. Interested 

persons are invited to send comments 

regarding the burden estimate or any 

other aspect of this collection of 

information, including the necessity and 

utility of the proposed information 

collection for the proper performance of 

the agency’s functions, the accuracy of 

the estimated burden, ways to enhance 

the quality, utility, and clarity of the 

information to be collected, and the use 

7402 Federal Register / Vol. 86, No. 17 / Thursday, January 28, 2021 / Notices 

of automated collection techniques or 

other forms of information technology to 

minimize the information collection 

burden. 

DATES: Comments on the collection(s) of 

information must be received by the 

OMB desk officer by March 1, 2021. 

ADDRESSES: Written comments and 

recommendations for the proposed 

information collection should be sent 

within 30 days of publication of this 

notice to www.reginfo.gov/public/do/ 

PRAMain. Find this particular 

information collection by selecting 

‘‘Currently under 30-day Review—Open 

for Public Comments’’ or by using the 

search function. 

To obtain copies of a supporting 

statement and any related forms for the 

proposed collection(s) summarized in 

this notice, you may make your request 

using one of following: 

1. Access CMS’ website address at 

website address at https://www.cms.gov/ 

Regulations-and-Guidance/Legislation/ 

PaperworkReductionActof1995/PRAListing.html. 

2. Call the Reports Clearance Office at 

(410) 786–1326. 

FOR FURTHER INFORMATION CONTACT: 

William Parham at (410) 786–4669. 

SUPPLEMENTARY INFORMATION: Under the 

Paperwork Reduction Act of 1995 (PRA) 

(44 U.S.C. 3501–3520), federal agencies 

must obtain approval from the Office of 

Management and Budget (OMB) for each 

collection of information they conduct 

or sponsor. The term ‘‘collection of 

information’’ is defined in 44 U.S.C. 

3502(3) and 5 CFR 1320.3(c) and 

includes agency requests or 

requirements that members of the public 

submit reports, keep records, or provide 

information to a third party. Section 

3506(c)(2)(A) of the PRA (44 U.S.C. 

3506(c)(2)(A)) requires federal agencies 

to publish a 30-day notice in the 

Federal Register concerning each 

proposed collection of information, 

including each proposed extension or 

reinstatement of an existing collection 

of information, before submitting the 

collection to OMB for approval. To 

comply with this requirement, CMS is 

publishing this notice that summarizes 

the following proposed collection(s) of 

information for public comment: 

1. Type of Information Collection 

Request: Extension of a currently 

approved collection; Title of 

Information Collection: Disclosure 

Requirement for the In-Office Ancillary 

Services Exception; Use: Section 6003 of 

the Affordable Care Act (ACA) 

established a new disclosure 

requirement that a physician must 

perform for certain imaging services to 

meet the in-office ancillary services 

exception to the prohibition of the 

physician self-referral law. This section 

of the ACA amended section 1877(b)(2) 

of the Act by adding a requirement that 

the referring physician informs the 

patient, at the time of the referral and in 

writing, that the patient may receive the 

imaging service from another supplier. 

Physicians who provide certain 

imaging services (MRI, CT, and PET) 

under the in-office ancillary services 

exception to the physician self-referral 

prohibition are required to provide the 

disclosure notice as well as the list of 

other imaging suppliers to the patient. 

The patient will then be able to use the 

disclosure notice and list of suppliers in 

making an informed decision about his 

or her course of care for the imaging 

service. 

CMS would use the collected 

information for enforcement purposes. 

Specifically, if we were investigating the 

referrals of a physician providing 

advanced imaging services under the inoffice ancillary services exception, we 

would review the written disclosure in 

order to determine if it satisfied the 

requirement. Form Number: CMS– 

10332 (OMB control number: 0938– 

1133); Frequency: Occasionally; 

Affected Public: Private Sector, Business 

or other for-profits, Not-for-profits 

institutions; Number of Respondents: 

2,239; Total Annual Responses: 

989,971; Total Annual Hours: 18,694. 

(For questions regarding this collection 

contact Laura Dash at 410–786–8623.) 

Dated: January 25, 2021. 

William N. Parham, III, 

Director, Paperwork Reduction Staff, Office 

of Strategic Operations and Regulatory 

Affairs. 

[FR Doc. 2021–01896 Filed 1–27–21; 8:45 am] 

BILLING CODE 4120–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Meeting of the Advisory Committee on 

Childhood Vaccines 

AGENCY: Health Resources and Services 

Administration (HRSA), Department of 

Health and Human Services (HHS). 

ACTION: Notice. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, this 

notice announces that the Advisory 

Committee on Childhood Vaccines 

(ACCV) will hold public meetings for 

the 2021 calendar year (CY). 

Information about the ACCV, agendas, 

and materials for these meetings can be 

found on the ACCV website at https:// 

www.hrsa.gov/advisory-committees/ 

vaccines. 

DATES: ACCV meetings will be held on: 

• March 4, 2021, 10:00 a.m. Eastern 

Time (ET)–4:00 p.m. ET; 

• June 3, 2021, 10:00 a.m. ET–4:00 

p.m. ET; 

• September 2, 2021, 10:00 a.m. ET– 

4:00 p.m. ET; 

• December 2, 2021, 10:00 a.m. ET– 

4:00 p.m. ET. 

ADDRESSES: Meetings may be held inperson or by teleconference and 

webinar. For updates on how the 

meeting will be held, visit the ACCV 

website 30 business days before the date 

of the meeting, where instructions for 

joining meetings either in-person and 

remotely will also be posted. In-person 

ACCV meetings will be held at 5600 

Fishers Lane, Rockville, Maryland 

20857. For meeting information 

updates, go to the ACCV website listed 

above. 

FOR FURTHER INFORMATION CONTACT: 

Annie Herzog, Division of Injury 

Compensation Programs, HRSA, 5600 

Fishers Lane, Rockville, Maryland 

20857; 301–443–6634; or ACCV@

HRSA.gov. 

SUPPLEMENTARY INFORMATION: The ACCV 

provides advice and recommendations 

to the Secretary of HHS on policy, 

program development, and other issues 

related to implementation of the 

National Vaccine Injury Compensation 

Program (VICP) and concerning other 

matters as described under section 2119 

of the Public Health Service Act (42 

U.S.C. 300aa–19). 

Since priorities dictate meeting times, 

be advised that times and agenda items 

are subject to change. Refer to the ACCV 

website listed above for any meeting 

updates that may occur. For CY 2021 

meetings, agenda items may include, 

but are not limited to updates from the 

Division of Injury Compensation 

Programs, Department of Justice, Office 

of Infectious Disease and HIV/AIDS 

Policy (HHS), Immunization Safety 

Office (Centers for Disease Control and 

Prevention), National Institute of 

Allergy and Infectious Diseases 

(National Institutes of Health) and 

Center for Biologics, Evaluation and 

Research (Food and Drug 

Administration). Refer to the ACCV 

website listed above for all current and 

updated information concerning the CY 

2021 ACCV meetings, including draft 

agendas and meeting materials that will 

be posted 5 calendar days before the 

meeting(s). 

Members of the public will have the 

opportunity to provide comments.